News

Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly
Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...
Nasdaq17d
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
Collaboration combines Novo ... small molecule therapies directed to one or more select G protein-coupled receptor (GPCR) targets, including the GLP-1, GIP and glucagon receptors. “Novo Nordisk ...
Victoria Advocate15d
Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills
FRIDAY, May 16, 2025 (HealthDay News) — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to ...